Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrol ...
Operator: Good morning, ladies and gentlemen, and welcome to Scholar Rock’s Third Quarter 2025 Conference Call. [Operator ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback